What question did this study set out to answer?

To evaluate the efficacy and safety of low-dose ATG with fractionated PTCY for GVHD prevention post-transplant.

December 8, 2025BloodOpen Access

Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis finds low-dose ATG and fractionated PTCY reduces GVHD incidence and improves outcomes in stem cell transplant recipients.

To evaluate the efficacy and safety of low-dose ATG with fractionated PTCY for GVHD prevention post-transplant.
Retrospective analysis of clinical data from 29 patients undergoing allo-HSCT.
Patients received low-dose ATG, fractionated low-dose PTCY, cyclosporine, and mycophenolate mofetil for GVHD prophylaxis.
Infections and adverse events were monitored post-transplant.
8.4% incidence of grade I–IV acute GVHD at D+100.
17.2% 1-year relapse rate noted among patients.
77.3% overall survival and 62.5% progression-free survival rates observed.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis finds low-dose ATG and fractionated PTCY reduces GVHD incidence and improves outcomes in stem cell transplant recipients.

To evaluate the efficacy and safety of low-dose ATG with fractionated PTCY for GVHD prevention post-transplant.
Retrospective analysis of clinical data from 29 patients undergoing allo-HSCT.
Patients received low-dose ATG, fractionated low-dose PTCY, cyclosporine, and mycophenolate mofetil for GVHD prophylaxis.
Infections and adverse events were monitored post-transplant.
8.4% incidence of grade I–IV acute GVHD at D+100.
17.2% 1-year relapse rate noted among patients.
77.3% overall survival and 62.5% progression-free survival rates observed.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark